Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung

Zusammenfassung

Eine erfolgreiche Therapie psychischer Störungen ist angesichts des häufig vorhandenen Leidensdrucks der Betroffenen sehr wichtig. Da anerkannte pharmazeutische und psychotherapeutische Ansätze leider nicht für alle Patient:innen zur erwünschten Besserung ihres Leidens führen, findet intensive Forschung zu ergänzenden oder alternativen Behandlungsmethoden statt. Besonders vielversprechend zeigte sich zuletzt die Psilocybin-gestützte Psychotherapie, die in den USA deshalb für klinische Studien mit größeren Stichproben als bisher zugelassen wurde. Psilocybin gehört zu den Psychedelika und beeinflusst in seiner Wirkung das psychische Erleben. Bei der gestützten Therapie wird Psilocybin in kontrollierten Dosen unter medizinischer Aufsicht verabreicht. In den bisher durchgeführten Studien konnten bereits nach einer, bis wenigen Einnahmen längerfristige positive Effekte in Hinblick auf die jeweiligen Störungsbilder gezeigt werden. Um ein besseres Verständnis der potenziellen therapeutischen Mechanismen zu ermöglichen, sollen in diesem Artikel zunächst Erkenntnisse zur Wirkweise von Psilocybin auf neurobiologischer und psychologischer Ebene vorgestellt werden. Anschließend soll die Analyse der bisher durchgeführten klinischen Studien mit einer Anwendung von Psilocybin bei Patient:innen helfen, das Potential der Psilocybin-gestützten Psychotherapie für verschiedene Störungsbilder besser einschätzen zu können.

Abstract

Successful therapy of mental disorders is very important in view of the high level of suffering of those affected. Since established pharmaceutical and psychotherapeutic approaches do not lead to the desired improvement in all cases, complementary or alternative treatment methods are intensively researched. Psilocybin-assisted psychotherapy seems particularly promising, and has been approved in the USA for larger clinical trials. Psilocybin belongs to the group of psychedelics and influences psychological experiences. In assisted therapy, psilocybin is administered in controlled doses under medical supervision to patients with different mental disorders. In the studies conducted so far, longer-term positive effects could be shown after just one or a few doses. In order to provide a better understanding of the potential therapeutic mechanisms, this article will first describe neurobiological and psychological effects of psilocybin. To better assess the potential of psilocybin-assisted psychotherapy for various disorders, clinical studies conducted so far with patients administered psilocybin are reviewed.

Schlüsselwörter

Psilocybin - Therapie - Depression - Neurobiologie - 5-HT-2A Rezeptor - Terminale Erkrankungen

Key words

Psilocybin - therapy - depression - neurobiology - 5-HT-2A receptor - terminal diseases

^‡ Diese Autorinnen/Autoren haben zu gleichen Teilen beigetragen und sind gemeinsame Erstautorinnen/Erstautoren.

Publication History

Received: 13 July 2021

Accepted: 23 February 2023

Article published online:
19 May 2023

• Literatur

• 1 Whiteford HA, Degenhardt L, Rehm J. et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet 2013; 382: 1575-1586 DOI: 10.1016/S0140-6736(13)61611-6.
• 2 Carhart-Harris RL, Bolstridge M, Rucker J. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3: 619-627 DOI: 10.1016/S2215-0366(16)30065-7.
• 3 Lewis CR, Preller KH, Kraehenmann R. et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. NeuroImage 2017; 159: 70-78 DOI: 10.1016/j.neuroimage.2017.07.020.
• 4 Grob CS, Grigsby J.. Handbook of Medical Hallucinogens. New York: Guilford Press; 2021
• 5 Vollenweider FX, Kometer M.. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010; 11: 642-651 DOI: 10.1017/CBO9780511980053.004.
• 6 Majić T, Schmidt TT, Gallinat J.. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences. J Psychopharmacol (Oxf) 2015; 29: 241-253 DOI: 10.1177/0269881114568040.
• 7 Hess P.. Psilocybin: FDA Grants „Breakthrough Therapy“ Status for Magic Mushrooms. Inverse. 2022 Im Internet https://www.inverse.com/article/50176-fda-okays-psilocybin-therapy-for-depression; Stand: 16.03.2022
• 8 Hehli S.. Vorwürfe wegen Sex und Drogen – die Kirschblütler kommen unter Druck. Neue Zür Ztg. 2019
• 9 Hehli S.. Psychiater missbraucht schwer traumatisierte Frau – und darf weiter praktizieren | NZZ. Neue Zür Ztg. 2018
• 10 Passie T, Seifert J, Schneider U. et al. The pharmacology of psilocybin. Addict Biol 2002; 7: 357-364 DOI: 10.1080/1355621021000005937.
• 11 Tylš F, Páleníček T, Horáček J.. Psilocybin--summary of knowledge and new perspectives. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2014; 24: 342-356 DOI: 10.1016/j.euroneuro.2013.12.006.
• 12 Horita A.. Some biochemical studies on psilocybin and psilogin. J Neuropsychiatry 1963; 4: 270-273 PMID: 13954906.
• 13 Ruban A, Kolodziej A.. Changes in default-mode network activity and functional connectivity as an indicator of psychedelic-assisted psychotherapy effectiveness. Neuropsychiatr Neuropsychol 2018; 13: 91-97 DOI: 10.5114/nan.2018.81249.
• 14 Ressler KJ, Nemeroff CB.. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12: 2-19 DOI: 10.1002/1520-6394(2000)12:1+<2:AID-DA2>3.0.CO;2-4.
• 15 Hornung J-P.. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003; 26: 331-343 DOI: 10.1016/j.jchemneu.2003.10.002.
• 16 Geyer MA, Vollenweider FX.. Serotonin research: Contributions to understanding psychoses. Trends Pharmacol Sci 2008; 29: 445-453 DOI: 10.1016/j.tips.2008.06.006.
• 17 Naughton M, Mulrooney JB, Leonard BE.. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol Clin Exp 2000; 15: 397-415 DOI: 10.1002/1099-1077(200008)15:6<397:AID-HUP212>3.0.CO;2-L.
• 18 Preller KH, Duerler P, Burt JB. et al. Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biol Psychiatry 2020; 88: 197-207 DOI: 10.1016/j.biopsych.2019.12.027.
• 19 Kraehenmann R, Preller KH, Scheidegger M. et al. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry 2015; 78: 572-581 DOI: 10.1016/j.biopsych.2014.04.010.
• 20 Kometer M, Schmidt A, Bachmann R. et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 2012; 72: 898-906 DOI: 10.1016/j.biopsych.2012.04.005.
• 21 Kraehenmann R, Schmidt A, Friston K. et al. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin 2016; 11: 53-60 DOI: 10.1016/j.nicl.2015.08.009.
• 22 Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport Int J Rapid Commun Res Neurosci 1998; 9: 3897-3902 DOI: 10.1097/00001756-199812010-00024.
• 23 Quednow BB, Kometer M, Geyer MA. et al. Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers. Neuropsychopharmacology 2012; 37: 630-640 DOI: 10.1038/npp.2011.228.
• 24 Raval NR, Johansen A, Donovan LL. et al. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. Int J Mol Sci 2021; 22: 835 DOI: 10.3390/ijms22020835.
• 25 Pazos A, Probst A, Palacios JM.. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21: 123-139 DOI: 10.1016/0306-4522(87)90327-7.
• 26 Carhart-Harris RL, Leech R, Williams TM. et al. Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 2012; 200: 238-244 DOI: 10.1192/bjp.bp.111.103309.
• 27 Carhart-Harris RL, Leech R, Hellyer PJ. et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 2014; 8: 20 DOI: 10.3389/fnhum.2014.00020.
• 28 Shao L-X, Liao C, Gregg I. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. 2021 2021.02.17.431629
• 29 Johnson MW, Hendricks PS, Barrett FS. et al. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. 2019; 197: 83-102 DOI: 10.1016/j.pharmthera.2018.11.010.
• 30 Vollenweider FX, Vontobel P, Hell D. et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in Man – A PET study with [11C]raclopride. Neuropsychopharmacology 1999; 20: 424-433 DOI: 10.1016/S0893-133X(98)00108-0.
• 31 Kyzar EJ, Nichols CD, Gainetdinov RR. et al. Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci 2017; 38: 992-1005 DOI: 10.1016/j.tips.2017.08.003.
• 32 Madsen MK, Fisher PMD. Stenb\a ek DS et al. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol 2020; 33: 71-80 DOI: 10.1016/j.euroneuro.2020.02.001.
• 33 Kometer M, Cahn BR, Andel D. et al. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry 2011; 69: 399-406 DOI: 10.1016/j.biopsych.2010.10.002.
• 34 Griffiths RR, Johnson MW, Carducci MA. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (Oxf) 2016; 30: 1181-1197 DOI: 10.1177/0269881116675513.
• 35 Grob CS, Danforth AL, Chopra GS. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68: 71-78 DOI: 10.1001/archgenpsychiatry.2010.116.
• 36 Ross S, Bossis A, Guss J. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol (Oxf) 2016; 30: 1165-1180 DOI: 10.1177/0269881116675512.
• 37 Griffiths RR, Richards WA, Johnson MW. et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol (Oxf) 2008; 22: 621-632 DOI: 10.1177/0269881108094300.
• 38 Roseman L, Demetriou L, Wall MB. et al. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology 2018; 142: 263-269 DOI: 10.1016/j.neuropharm.2017.12.041.
• 39 Griffiths RR, Richards WA, McCann U. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006; 187: 268-283 DOI: 10.1007/s00213-006-0457-5.
• 40 Griffiths RR, Johnson MW, Richards WA. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 2011; 218: 649-665 DOI: 10.1007/s00213-011-2358-5.
• 41 Stace WT.. Mysticism and Philosophy. 3rd ed. Edition. London: Palgrave Macmillan; 1960
• 42 Barrett FS, Griffiths RR.. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Curr Top Behav Neurosci 2018; 36: 393-430 DOI: 10.1007/7854_2017_474.
• 43 Barrett FS, Johnson MW, Griffiths RR.. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol Oxf Engl 2015; 29: 1182-1190 DOI: 10.1177/0269881115609019.
• 44 Miller WR.. The phenomenon of quantum change. J Clin Psychol 2004; 60: 453-460 DOI: 10.1002/jclp.20000.
• 45 Miller WR, C’de Baca J.. Quantum change: When epiphanies and sudden insights transform ordinary lives. New York: Guilford Press; 2001
• 46 Studerus E, Kometer M, Hasler F. et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol Oxf Engl 2011; 25: 1434-1452 DOI: 10.1177/0269881110382466.
• 47 Hendricks PS.. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry 2018; 30: 331-342 DOI: 10.1080/09540261.2018.1474185.
• 48 Erritzoe D, Roseman L, Nour MM. et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand 2018; 138: 368-378 DOI: 10.1111/acps.12904.
• 49 MacLean KA, Johnson MW, Griffiths RR.. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol (Oxf) 2011; DOI: 10.1177/0269881111420188.
• 50 Karlsson H, Hirvonen J, Salminen J. et al. Increased Serotonin Receptor 1A Binding in Major Depressive Disorder after Psychotherapy, but Not after SSRI Pharmacotherapy, Is Related to Improved Social Functioning Capacity. Psychother Psychosom 2013; 82: 260-261 DOI: 10.1159/000346143.
• 51 Yehuda R, Daskalakis NP, Desarnaud F. et al. Epigenetic Biomarkers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Veterans with PTSD. Front Psychiatry 2013; 4: 118 DOI: 10.3389/fpsyt.2013.00118.
• 52 Ziegler C, Richter J, Mahr M. et al. MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy. Transl Psychiatry 2016; 6: e773 DOI: 10.1038/tp.2016.41.
• 53 Carhart-Harris RL, Friston KJ.. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacol Rev 2019; 71: 316-344 DOI: 10.1124/pr.118.017160.
• 54 Carhart-Harris RL, Bolstridge M, Day CMJ. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235: 399-408 DOI: 10.1007/s00213-017-4771-x.
• 55 Friston K.. The free-energy principle: a unified brain theory. Nat Rev Neurosci 2010; 11: 127-138 DOI: 10.1038/nrn2787.
• 56 Friston K, Kiebel S.. Predictive coding under the free-energy principle. Philos Trans R Soc B Biol Sci 2009; 364: 1211 DOI: 10.1098/rstb.2008.0300.
• 57 Tappin BM, Gadsby S.. Biased belief in the Bayesian brain: A deeper look at the evidence. Conscious Cogn 2019; 68: 107-114 DOI: 10.1016/j.concog.2019.01.006.
• 58 Wolff M, Evens R, Mertens LJ. et al. Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Front Psychiatry 2020; 11: 5 DOI: 10.3389/fpsyt.2020.00005.
• 59 Walsh Z, Thiessen MS.. Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. Int Rev Psychiatry 2018; 30: 343-349 DOI: 10.1080/09540261.2018.1474088.
• 60 Madsen MK, Fisher PM, Burmester D. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 2019; 44: 1328-1334 DOI: 10.1038/s41386-019-0324-9.
• 61 Nour MM, Evans L, Nutt D. et al. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI. Front Hum Neurosci 2016; 10: 269 DOI: 10.3389/fnhum.2016.00269.
• 62 Bouso JC, dos Santos RG, Alcázar-Córcoles MÁ. et al. Serotonergic psychedelics and personality: A systematic review of contemporary research. Neurosci Biobehav Rev 2018; 87: 118-132 DOI: 10.1016/j.neubiorev.2018.02.004.
• 63 Martin DA, Nichols CD.. Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain. EBioMedicine 2016; 11: 262-277 DOI: 10.1016/j.ebiom.2016.08.049.
• 64 Crick FC, Koch C.. What is the function of the claustrum?. Philos Trans R Soc B Biol Sci 2005; 360: 1271-1279 DOI: 10.1098/rstb.2005.1661.
• 65 Goll Y, Atlan G, Citri A.. Attention: The claustrum. Trends Neurosci 2015; 38 DOI: 10.1016/j.tins.2015.05.006.
• 66 Preller KH, Pokorny T, Hock A. et al. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci 2016; 113: 5119-5124 DOI: 10.1073/pnas.1524187113.
• 67 Lee H, Roth B.. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A 2012; 109: 1820-1821 DOI: 10.1073/pnas.1121358109.
• 68 Buckner RL, Andrews-Hanna JR, Schacter DL.. The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008; 1124: 1-38 DOI: 10.1196/annals.1440.011.
• 69 Andrews-Hanna JR, Reidler JS, Sepulcre J. et al. Functional-Anatomic Fractionation of the Brain’s Default Network. Neuron 2010; 65: 550-562 DOI: 10.1016/j.neuron.2010.02.005.
• 70 Andrews-Hanna JR, Smallwood J, Spreng RN.. The default network and self-generated thought: component processes, dynamic control, and clinical relevance. Ann N Y Acad Sci 2014; 1316: 29-52 DOI: 10.1111/nyas.12360.
• 71 Whitfield-Gabrieli S, Ford JM.. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol 2012; 8: 49-76 DOI: 10.1146/annurev-clinpsy-032511-143049.
• 72 Karnath H-O, Thier P. Hrsg. Kognitive Neurowissenschaften. 3. Aufl. Berlin Heidelberg: Springer-Verlag; 2012
• 73 Leibenluft E, Pine DS.. Resting state functional connectivity and depression: in search of a bottom line. Biol Psychiatry 2013; 74: 868-869 DOI: 10.1016/j.biopsych.2013.10.001.
• 74 Seminowicz DA, Mayberg HS, McIntosh AR. et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. NeuroImage 2004; 22: 409-418 DOI: 10.1016/j.neuroimage.2004.01.015.
• 75 Grandjean J, Buehlmann D, Buerge M. et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage 2021; 225: 117456 DOI: 10.1016/j.neuroimage.2020.117456.
• 76 Carhart-Harris RL, Roseman L, Bolstridge M. et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 2017; 7: 13187 DOI: 10.1038/s41598-017-13282-7.
• 77 Volkow ND, Koob GF, McLellan AT.. Neurobiologic Advances from the Brain Disease Model of Addiction DOI: 10.1056/NEJMra1511480. 2016; Im Internet https://www.nejm.org/doi/10.1056/NEJMra1511480; Stand: 09.07.2021
• 78 Cole DM, Beckmann CF, Long CJ. et al. Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. NeuroImage 2010; 52: 590-599 DOI: 10.1016/j.neuroimage.2010.04.251.
• 79 Petri G, Expert P, Turkheimer F. et al. Homological scaffolds of brain functional networks. J R Soc Interface 2014; 11: 20140873 DOI: 10.1098/rsif.2014.0873.
• 80 Tagliazucchi E, Carhart-Harris R, Leech R. et al. Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 2014; 35: 5442-5456 DOI: 10.1002/hbm.22562.
• 81 Kometer M, Pokorny T, Seifritz E. et al. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl) 2015; 232: 3663-3676 DOI: 10.1007/s00213-015-4026-7.
• 82 Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ. et al. Broadband Cortical Desynchronization Underlies the Human Psychedelic State. J Neurosci 2013; 33: 15171-15183 DOI: 10.1523/JNEUROSCI.2063-13.2013.
• 83 Kometer M, Schmidt A, Jancke L. et al. Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations. J Neurosci 2013; 33: 10544-10551 DOI: 10.1523/JNEUROSCI.3007-12.2013.
• 84 Phelps EA, LeDoux JE.. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 2005; 48: 175-187 DOI: 10.1016/j.neuron.2005.09.025.
• 85 Dannlowski U, Ohrmann P, Bauer J. et al. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 2007; 6: 672-676 DOI: 10.1111/j.1601-183X.2006.00297.x.
• 86 Mertens LJ, Wall MB, Roseman L. et al. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol (Oxf) 2020; 34: 167-180 DOI: 10.1177/0269881119895520.
• 87 Moreno FA, Wiegand CB, Taitano EK. et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; DOI: 10.4088/JCP.v67n1110.
• 88 Johnson MW, Garcia-Romeu A, Griffiths RR.. Long-term Follow-up of Psilocybin-facilitated Smoking Cessation. Am J Drug Alcohol Abuse 2017; 43: 55-60 DOI: 10.1016/j.physbeh.2017.03.040.
• 89 Johnson MW, Garcia-Romeu A, Cosimano MP. et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol (Oxf) 2014; DOI: 10.1177/0269881114548296.
• 90 Bogenschutz MP, Alyssa Forcehimes, Pommy JA. et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol (Oxf) 2015; 29: 289-299 DOI: 10.1177/0269881114565144.
• 91 Davis AK, Barrett FS, May DG. et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2020; DOI: 10.1001/jamapsychiatry.2020.3285.
• 92 Al-Naggar RA, Alshaikhli H, Erlam G.. Effectiveness of Psilocybin on Depression: A Qualitative Study. Electron J Gen Med 2021; 18: em296 DOI: 10.29333/ejgm/10862.
• 93 Agin-Liebes G, Ekman E, Anderson B. et al. Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis. J Humanist Psychol 2021; 00221678211022949 DOI: 10.1177/00221678211022949.
• 94 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996; 17: 1-12 DOI: 10.1016/0197-2456(95)00134-4.
• 95 Reiff CM, Richman EE, Nemeroff CB. et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry 2020; 177: 391-410 DOI: 10.1176/appi.ajp.2019.19010035.
• 96 Horton D, Morrison B, Schmidt J.. Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. Am J Psychother 2021; 74 appi.psychother DOI: 10.1176/appi.psychotherapy.20200055.
• 97 Garcia-Romeu A, Richards WA.. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry Abingdon Engl 2018; 30: 291-316 DOI: 10.1080/09540261.2018.1486289.
• 98 Li N-X, Hu Y-R, Chen W-N. et al. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord 2022; 296: 26-34 DOI: 10.1016/j.jad.2021.09.041.
• 99 Koslowski M, Betzler F, Gründer G. et al. Therapie mit Psychedelika – die Rolle der Psychotherapie. NeuroTransmitter 2020; 31: 32-37 DOI: 10.1007/s15016-020-7549-z.
• 100 Grof S, Goodman LE, Richards WA. et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 1973; 8: 129-144 DOI: 10.1159/000467984.
• 101 Grof S, Halifax J.. Human Encounter with Death. New York: E.P. Dutton; 1977
• 102 Johnson M, Richards W, Griffiths R.. Human hallucinogen research: guidelines for safety. J Psychopharmacol Oxf Engl 2008; 22: 603-620 DOI: 10.1177/0269881108093587.
• 103 Doss MK, Považan M, Rosenberg MD. et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry 2021; 11: 574 DOI: 10.1038/s41398-021-01706-y.
• 104 Gukasyan N, Davis AK, Barrett FS. et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol (Oxf) 2022; 36: 151-158 DOI: 10.1177/02698811211073759.
• 105 Bogenschutz MP.. Studying the effects of classic hallucinogens in the treatment of alcoholism: Rationale, methodology, and current research with psilocybin. Curr Drug Abuse Rev 2013; 6: 17-29 DOI: 10.2174/15733998113099990002.
• 106 Bogenschutz MP, Podrebarac SK, Duane JH. et al. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Front Pharmacol 2018; 9 DOI: 10.3389/fphar.2018.00100.
• 107 Miller WR, Zweben A, Di Clemente CC. et al. Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Alcohol Abuse and Alcoholism. 1992
• 108 Hallock RM, Dean A, Knecht ZA. et al. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug Alcohol Depend 2013; 130: 245-248 DOI: 10.1016/j.drugalcdep.2012.11.010.
• 109 dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ. et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol 2018; 11: 889-902 DOI: 10.1080/17512433.2018.1511424.
• 110 Johnson MW, Andrew Sewell R, Griffiths RR.. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 2012; 123: 132-140 DOI: 10.1016/j.drugalcdep.2011.10.029.
• 111 Rubin A, Yu M.. Within-Group Effect Size Benchmarks for Cognitive–Behavioral Therapy in the Treatment of Adult Depression. Soc Work Res 2017; 41: 1-10 DOI: 10.1093/swr/svx011.
• 112 Fournier JC, DeRubeis RJ, Hollon SD. et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53 DOI: 10.1001/jama.2009.1943.
• 113 Carhart-Harris R, Giribaldi B, Watts R. et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384: 1402-1411 DOI: 10.1056/NEJMoa2032994.
• 114 Muthukumaraswamy SD, Forsyth A, Lumley T.. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol 2021; 14: 1133-1152 DOI: 10.1080/17512433.2021.1933434.
• 115 Keers R, Aitchison KJ.. Gender differences in antidepressant drug response. Int Rev Psychiatry 2010; 22: 485-500 DOI: 10.3109/09540261.2010.496448.
• 116 Gorman JM.. Gender differences in depression and response to psychotropic medication. Gend Med 2006; 3: 93-109 DOI: 10.1016/S1550-8579(06)80199-3.